查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1404004

全球多囊性卵巢症候群治療市場-全球產業分析,規模,份額,成長,趨勢,預測(2031)-按藥物類別、按分銷管道、按地區

Polycystic Ovary Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 306 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

預計到2024年底，多囊性卵巢症候群（PCOS）治療的全球市場規模將達到42億美元，到2031年預計將大幅擴大至61.1億美元。多囊性卵巢症候群是一種影響女性的複雜內分泌疾病，其特徵是卵巢囊腫、不孕症和內分泌波動。

多囊性卵巢症候群（PCOS）是一項重大的全球健康挑戰，影響著全球數百萬名女性。根據世界衛生組織 (WHO) 統計，全球有超過 1.16 億女性 (3.4%) 患有 PCOS。光是在美國，PCOS 就影響了 6% 至 12% 的育齡女性，是女性不孕的主要原因。

多囊性卵巢症候群不限於特定年齡組，甚至在停經後女性中也可能持續存在，導致代謝變化和心血管疾病風險增加。早期診斷和治療不僅對於緩解症狀至關重要，而且對於預防長期影響也至關重要。

隨著人們對多囊性卵巢症候群及其相關風險的認識不斷提高，對診斷和治療的需求也在增加。PCOS 意識協會 (PCOSAA) 等意識計畫和倡議正在幫助提高診斷率。

為了應對不斷增加的多囊性卵巢症候群診斷數量，製造商正在增加其提供的藥物和營養補充劑的種類。創新的替代方案和改進的治療方法預計將提高採用率。

FDA 核准的 PCOS 治療方法數量有限，迫使個人使用適應不同目的的標籤外治療方法。缺乏 FDA 批准的針對 PCOS 相關症狀的治療方法阻礙了市場的成長。

在欠發達經濟體中，人們對多囊性卵巢症候群及其症狀的認知仍然很低。再加上缺乏了解和對治療的無憂無慮的態度，可能會阻礙市場的擴張。

該報告研究了全球多囊性卵巢症候群治療市場，並提供了市場概況，包括按藥物類別、分銷管道、地區劃分的趨勢以及進入市場的公司的競爭趨勢。

目錄

第一章執行摘要

第二章市場概況

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • COVID-19 影響分析
  • 烏克蘭與俄羅斯衝突的影響
  • 經濟概況
  • PESTLE分析

第三章 2018-2031 年全球多囊性卵巢症候群 (PCOS) 治療市場展望

  • 全球多囊性卵巢症候群 (PCOS) 治療市場展望，按藥物類別、價值（十億美元），2018-2031 年
  • 全球多囊性卵巢症候群 (PCOS) 治療市場展望（按分銷管道）、價值（十億美元），2018-2031 年
  • 全球多囊性卵巢症候群 (PCOS) 治療市場展望（按地區、價值（十億美元）），2018-2031 年

第四章 2018-2031 年北美多囊性卵巢症候群 (PCOS) 治療市場展望

第五章 2018-2031 年歐洲多囊性卵巢症候群 (PCOS) 治療市場展望

第六章 2018-2031 年亞太地區多囊性卵巢症候群 (PCOS) 治療市場展望

第 7 章 2018-2031 年拉丁美洲多囊性卵巢症候群 (PCOS) 治療市場展望

第 8 章 2018-2031 年中東和非洲多囊性卵巢症候群 (PCOS) 治療市場展望

第9章 競爭格局

  • 按藥物類別和分銷管道劃分的熱圖
  • 2023 年公司市場份額分析
  • 競爭力儀表板
  • 公司簡介
    • Novartis AG
    • Sanofi
    • Teva Pharmaceutical Industries Limited
    • Merck & Co., Inc. (Merck group)
    • AstraZeneca plc.
    • Bayer AG
    • Abbott
    • Pfizer, Inc
    • Bristol-Myer Squibb Company
    • Ferring Pharmaceuticals, Inc.
    • Johnson and Johnson
    • Mylan N.V.
    • Allergan plc.
    • GlaxoSmithKline
    • Lupin Pharmaceuticals
    • AbbVie
    • Takeda
    • BIOCAD Global
    • Blairex Laboratories Inc

第10章附錄

簡介目錄

The global polycystic ovary syndrome (PCOS) treatment market, valued at US$ 4.2 billion at the end of 2024, is forecasted to witness substantial growth, with an estimated valuation of US$ 6.11 billion by 2031. PCOS, a complex endocrine condition affecting women, is characterized by ovarian cysts, subfertility, and endocrine variations.

PCOS: A Global Health Concern

Polycystic ovarian syndrome (PCOS) poses a significant global health challenge, affecting millions of women worldwide. According to the World Health Organization (WHO), over 116 million women (3.4%) globally suffer from PCOS. In the United States alone, PCOS accounts for 6% to 12% of cases among women of reproductive age, making it a leading cause of female infertility.

PCOS is not limited to a specific age group, as it can persist even in postmenopausal women, leading to metabolic changes and an increased risk of cardiovascular disease. Early diagnosis and treatment are crucial not only to alleviate symptoms but also to prevent long-term consequences.

Opportunities for PCOS Drug Manufacturers:

Changing Lifestyles and Rising Awareness: With a growing awareness of PCOS and its associated risks, there is an increasing demand for diagnosis and treatment. Awareness programs and initiatives, such as PCOS Awareness Association (PCOSAA), are contributing to higher diagnosis rates.

Innovative Treatment Modalities: Manufacturers are offering an expanded range of drug formulations and dietary products to cater to the rising number of PCOS diagnoses. Innovative alternatives and improved treatment options are expected to boost adoption rates.

Challenges Faced by Market Players:

Unavailability of FDA-Approved Drugs: Limited FDA-approved drugs for PCOS treatment force individuals to use off-label drugs intended for different purposes. The absence of FDA-approved treatments for PCOS-related symptoms hinders market growth.

Lack of Awareness in Underdeveloped Economies: In underdeveloped economies, awareness regarding PCOS and its symptoms remains significantly low. This, coupled with a lack of understanding and a carefree attitude towards treatment, can hinder market expansion.

Country-Wise Insights:

Lucrative U.S. Market: The United States experiences rising healthcare costs and an increasing prevalence of PCOS-related disorders. Improved healthcare infrastructure, rising disposable income, and government-led awareness initiatives contribute to market growth.

Growing Indian Market: India has witnessed a surge in PCOS diagnoses, with approximately 22.5% of women affected. Increased awareness, changing lifestyles, and dietary habits are driving the demand for PCOS treatment in the country.

Competitive Landscape:

Leading manufacturers and pharmaceutical companies are focusing on developing innovative products to strengthen their global product pipelines. Collaborations and consolidation activities with other firms are being pursued to expedite research, development, and distribution.

Key Companies Profiled:

  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Limited
  • Merck & Co., Inc. (Merck group)
  • AstraZeneca plc.
  • Bayer AG
  • Abbott
  • Pfizer, Inc
  • Bristol-Myer Squibb Company
  • Ferring Pharmaceuticals, Inc.
  • Johnson and Johnson
  • Mylan N.V.
  • Allergan plc.
  • GlaxoSmithKline
  • Lupin Pharmaceuticals
  • AbbVie
  • Takeda
  • BIOCAD Global
  • Blairex Laboratories Inc
  • Agile Therapeutics

Key Segments of PCOS Treatment Industry Research

By Drug Class:

  • Oral Contraceptives
  • Insulin Sensitizing Agents
  • Antidepressants
  • Ornithine Decarboxylase Inhibitors
  • Aromatase Inhibitors & SERMs
  • Diuretics

By Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores/OTC
  • e-Commerce
  • Clinics

By Region:

  • North America
  • Latin America
  • Europe Polycystic
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Oral Contraceptives
      • 3.1.1.2. Insulin Sensitizing Agents
      • 3.1.1.3. Antidepressants
      • 3.1.1.4. Ornithine Decarboxylase Inhibitors
      • 3.1.1.5. Aromatase Inhibitors & SERMs
      • 3.1.1.6. Diuretics
  • 3.2. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospital Pharmacies
      • 3.2.1.2. Drug Stores/OTC
      • 3.2.1.3. e-Commerce
      • 3.2.1.4. Clinics
  • 3.3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Oral Contraceptives
      • 4.1.1.2. Insulin Sensitizing Agents
      • 4.1.1.3. Antidepressants
      • 4.1.1.4. Ornithine Decarboxylase Inhibitors
      • 4.1.1.5. Aromatase Inhibitors & SERMs
      • 4.1.1.6. Diuretics
  • 4.2. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospital Pharmacies
      • 4.2.1.2. Drug Stores/OTC
      • 4.2.1.3. e-Commerce
      • 4.2.1.4. Clinics
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Oral Contraceptives
      • 5.1.1.2. Insulin Sensitizing Agents
      • 5.1.1.3. Antidepressants
      • 5.1.1.4. Ornithine Decarboxylase Inhibitors
      • 5.1.1.5. Aromatase Inhibitors & SERMs
      • 5.1.1.6. Diuretics
  • 5.2. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospital Pharmacies
      • 5.2.1.2. Drug Stores/OTC
      • 5.2.1.3. e-Commerce
      • 5.2.1.4. Clinics
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Oral Contraceptives
      • 6.1.1.2. Insulin Sensitizing Agents
      • 6.1.1.3. Antidepressants
      • 6.1.1.4. Ornithine Decarboxylase Inhibitors
      • 6.1.1.5. Aromatase Inhibitors & SERMs
      • 6.1.1.6. Diuretics
  • 6.2. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospital Pharmacies
      • 6.2.1.2. Drug Stores/OTC
      • 6.2.1.3. e-Commerce
      • 6.2.1.4. Clinics
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Oral Contraceptives
      • 7.1.1.2. Insulin Sensitizing Agents
      • 7.1.1.3. Antidepressants
      • 7.1.1.4. Ornithine Decarboxylase Inhibitors
      • 7.1.1.5. Aromatase Inhibitors & SERMs
      • 7.1.1.6. Diuretics
  • 7.2. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospital Pharmacies
      • 7.2.1.2. Drug Stores/OTC
      • 7.2.1.3. e-Commerce
      • 7.2.1.4. Clinics
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Oral Contraceptives
      • 8.1.1.2. Insulin Sensitizing Agents
      • 8.1.1.3. Antidepressants
      • 8.1.1.4. Ornithine Decarboxylase Inhibitors
      • 8.1.1.5. Aromatase Inhibitors & SERMs
      • 8.1.1.6. Diuretics
  • 8.2. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospital Pharmacies
      • 8.2.1.2. Drug Stores/OTC
      • 8.2.1.3. e-Commerce
      • 8.2.1.4. Clinics
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Drug Class vs by Distribution Channel Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novartis AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Therapy Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Sanofi
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Therapy Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Teva Pharmaceutical Industries Limited
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Therapy Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Merck & Co., Inc. (Merck group)
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Therapy Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. AstraZeneca plc.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Therapy Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Bayer AG
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Therapy Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Abbott
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Therapy Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Pfizer, Inc
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Therapy Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Bristol-Myer Squibb Company
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Therapy Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Ferring Pharmaceuticals, Inc.
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Therapy Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Johnson and Johnson
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Therapy Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Mylan N.V.
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Therapy Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development
    • 9.4.13. Allergan plc.
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Therapy Portfolio
      • 9.4.13.3. Financial Overview
      • 9.4.13.4. Business Strategies and Development
    • 9.4.14. GlaxoSmithKline
      • 9.4.14.1. Company Overview
      • 9.4.14.2. Therapy Portfolio
      • 9.4.14.3. Financial Overview
      • 9.4.14.4. Business Strategies and Development
    • 9.4.15. Lupin Pharmaceuticals
      • 9.4.15.1. Company Overview
      • 9.4.15.2. Therapy Portfolio
      • 9.4.15.3. Financial Overview
      • 9.4.15.4. Business Strategies and Development
    • 9.4.16. AbbVie
      • 9.4.16.1. Company Overview
      • 9.4.16.2. Therapy Portfolio
      • 9.4.16.3. Financial Overview
      • 9.4.16.4. Business Strategies and Development
    • 9.4.17. Takeda
      • 9.4.17.1. Company Overview
      • 9.4.17.2. Therapy Portfolio
      • 9.4.17.3. Financial Overview
      • 9.4.17.4. Business Strategies and Development
    • 9.4.18. BIOCAD Global
      • 9.4.18.1. Company Overview
      • 9.4.18.2. Therapy Portfolio
      • 9.4.18.3. Financial Overview
      • 9.4.18.4. Business Strategies and Development
    • 9.4.19. Blairex Laboratories Inc
      • 9.4.19.1. Company Overview
      • 9.4.19.2. Therapy Portfolio
      • 9.4.19.3. Financial Overview
      • 9.4.19.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations